BioCentury
ARTICLE | Company News

Optimer, AstraZeneca sales and marketing update

December 10, 2012 8:00 AM UTC

Optimer granted AstraZeneca exclusive rights to commercialize Dificid fidaxomicin in South and Central America, Mexico and the Caribbean. Optimer will receive $1 million up front and is eligible for up to $3 million in milestones for the first commercial sale in certain countries. The company is also eligible for up to $19 million in sales based milestones, plus double-digit royalties. ...